Zai Lab Limited (9688) Stock News & Analysis

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

That timing matters today because Zai Lab Limited is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for schizophrenia, plus updates tied to China’s National Reimbursement Drug List and progress in a key oncology program. Business Wire

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

December 24, 2025 — Zai Lab Limited is back in the spotlight after a major regulatory catalyst in China helped lift sentiment around the biopharma name. The company announced that China’s National Medical Products Administration approved COBENFY for schizophrenia in adults—a decision that quickly rippled into trading on both its U.S. ADR and Hong Kong listings. Business Wire+1

24 December 2025

HKG:9688·NASDAQ:ZLAB·Pharmaceuticals·Stock Market